US Patent 7,855,217: What Is Claimed, What It Covers, and Where It Sits in the US Patent Landscape
US Patent 7,855,217 is a solid-form patent centered on crystalline hemihydrate of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (the “API”) and downstream pharmaceutical compositions using that specific solid form. The claims are composition-of-matter in the solid-state sense (polymorph/solvate/hemihydrate fraction) and then composition for dosing.
The scope is narrow at the solid-form level (hemihydrate + high purity by weight), then broader at the dosage-form level (any unit dosage using that solid form at specified dose ranges).
What exactly do the claims cover?
1) Solid form claim: crystalline hemihydrate with a minimum hemihydrate fraction
Claims 1–4 are directed to:
- A “solid form” of the API
- comprising crystalline API hemihydrate
- with the crystalline hemihydrate present at greater than a threshold by weight of the solid form
Claim language structure (all 1–4)
- “A solid form of [API] comprising crystalline [API] hemihydrate”
- “wherein the crystalline [API] hemihydrate is present at greater than about X% by weight of the solid form”
| Threshold ladder |
Claim |
Crystalline hemihydrate present at > about (% wt) |
Scope effect |
| 1 |
80% |
Broadest solid-form definition |
| 2 |
90% |
Excludes solids with more other forms than claim 1 allows |
| 3 |
95% |
Tight purity requirement |
| 4 |
97% |
Tightest solid-form definition |
Key scope point
- This is not merely “hemihydrate exists.” It requires that the crystalline hemihydrate is the dominant component of the solid form by weight fraction.
2) Composition claims: pharmaceutical composition using that solid form
Claims 5–10 cover:
- A pharmaceutical composition
- containing a therapeutically effective amount of the solid form of claims 1–4
- plus pharmaceutically acceptable excipient/carrier
Then the claims narrow/define:
- single unit dosage form (claim 6)
- therapeutically effective amount at specific dose levels (claims 7–10)
| Dosage specificity |
Claim |
Therm. effective amount |
Form factor |
| 5 |
“therapeutically effective amount” (not fixed) |
composition + carrier |
| 6 |
(depends on claim 5) |
single unit dosage form |
| 7 |
about 5 mg |
single unit dosage (via claim 6) |
| 8 |
about 10 mg |
single unit dosage (via claim 6) |
| 9 |
about 25 mg |
single unit dosage (via claim 6) |
| 10 |
about 50 mg |
single unit dosage (via claim 6) |
Key scope point
- The dose claims are mg-level points (5, 10, 25, 50 mg), not a wide range. The patent landscape impact depends on whether competitors dose at those specific levels with the claimed hemihydrate solid form.
What is the functional boundary of infringement risk?
1) Solid form boundary
For literal infringement on claims 1–4, a product must be:
- the API in crystalline hemihydrate form, and
- the crystalline hemihydrate must be present above the claim threshold by weight:
-
80% (claim 1)
-
90% (claim 2)
-
95% (claim 3)
-
97% (claim 4)
Practical implication: products containing significant fractions of other solvates/polymorphs/anhydrate forms can fall outside the claims if they drop below the threshold.
2) Carrier and unit dose boundary
Claims 5–6 are broad as to excipient type and dosage presentation, limited mainly by “pharmaceutically acceptable excipient or carrier” and “single unit dosage form.”
Claims 7–10 are limited to dose amounts (about 5/10/25/50 mg). Products at other unit strengths may still be captured by claim 5, depending on whether the “therapeutically effective amount” maps to the accused dosing regimen and how “about” is construed.
What does this mean for the patent landscape in the US?
1) This is a solid-form exclusivity layer
US 7,855,217 is best understood as a crystalline hemihydrate fraction exclusivity patent. It typically sits alongside:
- earlier process/synthesis or API patents, and
- later formulation/polymorph patents for life-cycle management.
Because the claims explicitly require a hemihydrate with high weight fraction, the main landscape questions for freedom-to-operate (FTO) are:
- whether competitors use hemihydrate, and
- whether their solid-state composition stays above the relevant % wt thresholds.
2) Likely landscape pressure points
Within the same chemical entity family, it is common for patent families to include:
- multiple solid forms (anhydrate, hydrates, polymorphs, solvates),
- compositional claims based on phase purity,
- formulation claims using those solid forms.
The presence of a threshold ladder in claims 1–4 creates a litigation leverage point:
- If competitors can reproducibly shift their product below a given threshold (for example, by maintaining a mixed solid form), they can aim to avoid specific claims.
- Conversely, if their solid form is highly enriched hemihydrate, they are at higher risk across multiple claims.
Where do the claim types place the patent in enforcement strategy?
Solid-form claims (1–4): target manufacturing and solid-state control
- These claims are directed to a “solid form,” which typically ties to manufacturing controls, crystallization conditions, and incoming/outgoing solid-state characterization.
- Enforcement often focuses on analytical evidence of hydrate content (by weight) and crystalline identity.
Composition claims (5–10): target finished dosage manufacturing and packaging
- Claims 5–6 target end-product compositions and dosage units.
- Claims 7–10 target unit strengths at about 5, 10, 25, and 50 mg.
- This creates a dual pathway for asserting infringement: either the accused API solid form matches the hemihydrate threshold, or the final formulation does.
Competitive design-around map (based strictly on claim language)
Design-around levers
-
Avoid crystalline hemihydrate as the dominant form
- If the product’s crystalline hemihydrate fraction by weight is kept below the relevant threshold, it can fall outside claims 1–4.
-
Use a different solid form
- The claims are tethered to “crystalline [API] hemihydrate.”
- Products based on anhydride or other hydrate forms can avoid literal coverage.
-
Unit strength positioning
- Claims 7–10 are dose-specific (about 5/10/25/50 mg).
- A different unit strength can reduce exposure to claims 7–10, but it does not automatically avoid claim 5 unless the accused product can also avoid “therapeutically effective amount” mapping.
Key claim-to-scope translation (executive view)
| Claim set |
What must be present |
What it captures |
Main exclusion path |
| 1–4 |
crystalline API hemihydrate at >80/90/95/97 wt% |
solid-form composition dominated by hemihydrate |
shift hemihydrate fraction below threshold or use different hydrate/polymorph |
| 5 |
therapeutically effective amount of claims 1–4 solid + excipient |
dosage formulation using the claimed solid form |
avoid claimed solid form or avoid therapeutic dosing interpretation |
| 6 |
claim 5 + single unit dosage form |
finished units |
change dosing presentation (multi-unit formats may still be challenged under claim 5) |
| 7–10 |
claim 5 + about 5/10/25/50 mg per unit |
specific strengths |
choose different unit strength to reduce claim 7–10 coverage (claim 5 may remain) |
What is missing from the record provided here (and how that limits landscape conclusions)
The user provided claim text only. The following landscape elements cannot be derived from the claim excerpt alone, so no product-level or family-level conclusions are included here:
- patent priority dates, filing/publication dates, and expiration schedule
- prosecution history, claim amendments, or allowed/withdrawn subject matter
- whether claims are subject to terminal disclaimers, reexams, or PTA/PTAB events
- whether US 7,855,217 belongs to a larger family with continuations or co-pending applications
- whether the API corresponds to a named drug with known branded/generic competitors
Accordingly, this analysis focuses on scope and enforceability boundaries created by the specific claim language.
Key Takeaways
- US 7,855,217 is a crystalline hemihydrate fraction patent: the API hemihydrate must be present at >80%, >90%, >95%, or >97% by weight, depending on claim 1–4.
- The patent extends to pharmaceutical compositions using that solid form (claims 5–6), then further narrows to single unit dosage and specific unit strengths of about 5, 10, 25, and 50 mg (claims 7–10).
- The highest infringement risk sits with products that (i) use the crystalline hemihydrate and (ii) maintain high hemihydrate weight fraction in finished solids.
- The most direct design-around is to avoid crystalline hemihydrate dominance by keeping the hemihydrate content below the relevant threshold or using a different solid form.
FAQs
1) Does the patent cover any hydrate form, or specifically hemihydrate?
It specifically requires crystalline API hemihydrate. Claims 1–4 are limited to the crystalline hemihydrate with defined weight fraction thresholds.
2) What is the broadest solid-form claim threshold in US 7,855,217?
Claim 1 requires > about 80% by weight crystalline hemihydrate in the solid form.
3) Can a competitor avoid claims 7–10 by changing tablet strength?
A competitor can reduce exposure to claims 7–10 by using unit strengths other than about 5/10/25/50 mg, but claim 5 can still apply if the formulation uses the claimed solid form at a “therapeutically effective amount.”
4) Are excipients and carriers limited?
No. Claims require only “a pharmaceutically acceptable excipient or carrier,” so excipient choice is not a meaningful limitation in the claim text.
5) Is there coverage for finished dosage forms beyond single-unit dosing?
The explicit language in claim 6 is “single unit dosage form.” Claim 5 covers the composition concept more generally, but the provided claim set includes explicit single-unit narrowing in claim 6 onward.
References
[1] US Patent 7,855,217 (claims provided in user prompt).
